ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis

Target: FUS Composite Score: 0.606 Price: $0.60 Citation Quality: Pending neurodegeneration Status: promoted
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
B
Composite: 0.606
Top 11% of 512 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.72 Top 46%
B Evidence Strength 15% 0.68 Top 42%
B Novelty 12% 0.65 Top 80%
A Feasibility 12% 0.80 Top 25%
B+ Impact 12% 0.70 Top 49%
A Druggability 10% 0.85 Top 24%
B Safety Profile 8% 0.62 Top 36%
C+ Competition 6% 0.58 Top 79%
B+ Data Availability 5% 0.75 Top 30%
B+ Reproducibility 5% 0.70 Top 31%
Evidence
5 supporting | 3 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenesis?

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate dynamics, but doesn't address how FUS mutations in ALS/FTD might disrupt this function. This gap is critical since FUS mutations cause neurodegeneration, yet this newly discovered role in transcriptional regulation remains unexplored in disease context. Gap type: open_question Source paper: A chaperone-like function of FUS ensures TAZ condensate dynamics and transcriptional activation. (None, None, PMID:38172614)

→ View full analysis & debate transcript

Description

Allele-specific ASOs targeting mutant FUS exons preserve wild-type FUS expression while eliminating pathogenic gain-of-function, restoring proper FUS-TAZ regulatory interaction and TAZ condensate dynamics.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.72 (15%) Evidence 0.68 (15%) Novelty 0.65 (12%) Feasibility 0.80 (12%) Impact 0.70 (12%) Druggability 0.85 (10%) Safety 0.62 (8%) Competition 0.58 (6%) Data Avail. 0.75 (5%) Reproducible 0.70 (5%) 0.606 composite
8 citations 6 with PMID Validation: 0% 5 supporting / 3 opposing
Evidence Matrix — sortable by strength/year, click Abstract to expand
ClaimTypeSourceStrength ↕Year ↕PMIDsAbstract
Jacifusen (ASO-FUS) has entered clinical testing f…Supporting---PMID:40414239-
DNAJB6 promotes non-toxic FUS condensate gelation …Supporting---PMID:41271702-
FUS mutations cause loss of dynamic RNA interactio…Supporting---PMID:31630970-
FUS R521G promotes ALS-associated phenotypes inclu…Supporting---PMID:37974279-
ASOs are validated modality for neurological disea…Supporting-----
FUS is essential with multiple functions; complete…Opposing---PMID:21358643-
Jacifusen approach is general FUS knockdown, not s…Opposing---PMID:40414239-
ASO delivery to CNS requires intrathecal administr…Opposing-----
Legacy Card View — expandable citation cards

Supporting Evidence 5

Jacifusen (ASO-FUS) has entered clinical testing for FUS-ALS, demonstrating feasibility of ASO approach target…
Jacifusen (ASO-FUS) has entered clinical testing for FUS-ALS, demonstrating feasibility of ASO approach targeting mutant FUS
DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity, demonstrating chaperone-based mo…
DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity, demonstrating chaperone-based modulation of FUS phase separation is viable
FUS mutations cause loss of dynamic RNA interaction and aberrant phase separation, establishing aberrant LLPS …
FUS mutations cause loss of dynamic RNA interaction and aberrant phase separation, establishing aberrant LLPS as a pathogenic mechanism amenable to correction
FUS R521G promotes ALS-associated phenotypes including loss of dendritic branching and synapses in motor neuro…
FUS R521G promotes ALS-associated phenotypes including loss of dendritic branching and synapses in motor neurons
ASOs are validated modality for neurological diseases with multiple FDA approvals (nusinersen, tofersen, etepl…
ASOs are validated modality for neurological diseases with multiple FDA approvals (nusinersen, tofersen, eteplirsen)

Opposing Evidence 3

FUS is essential with multiple functions; complete knockdown may cause toxicity - therapeutic window between p…
FUS is essential with multiple functions; complete knockdown may cause toxicity - therapeutic window between pathologic aggregation and normal function may be narrow
Jacifusen approach is general FUS knockdown, not specifically restoring FUS-TAZ axis - mechanism distinction f…
Jacifusen approach is general FUS knockdown, not specifically restoring FUS-TAZ axis - mechanism distinction from hypothesis is unclear
ASO delivery to CNS requires intrathecal administration with associated risks
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

0.590.610.62 0.63 0.58 2026-04-152026-04-152026-04-15 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (5)

Paper:21358643
No extracted figures yet
Paper:31630970
No extracted figures yet
Paper:37974279
No extracted figures yet
Paper:40414239
No extracted figures yet
Paper:41271702
No extracted figures yet

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

KG Entities (2)

FUSneurodegeneration

Related Hypotheses

SASP-Mediated Complement Cascade Amplification
Score: 0.703 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.692 | neurodegeneration
H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector
Score: 0.675 | neurodegeneration
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.670 | neurodegeneration
Transcriptional Autophagy-Lysosome Coupling
Score: 0.665 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (1 edges)

promoted: ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis (1)

FUS neurodegeneration

3D Protein Structure

🧬 FUS — PDB 4FDD Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenesis?

neurodegeneration | 2026-04-14 | failed